Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...

Austin Chiang, MD, MPH: One innovation that's happening in my specialty of gastroenterology is artificial intelligence. Ben ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Home with Dignity, a leading mobile in-home euthanasia service for pets, now offers Phoenix pet owners a compassionate ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

Alcohol use disorder is a prevalent and major but preventable cause of morbidity and mortality worldwide, causing several ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...